Through an unbiased chemical-genetic screen, we identified Brd4 as an epigenetic regulator required for maintaining the Jun/PTF CRC, and showed that Yap-independent PDAC tumors with high PTF expression are very sensitive to BET inhibitors (Fig. 8). The gene discussed is JUN; the disease is colorectal carcinoma.